首页> 外文期刊>AIDS Research and Human Retroviruses >New subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010)
【24h】

New subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010)

机译:秘鲁采用高效抗逆转录病毒治疗的感染HIV 1的患者的新亚型和基因重组(2008-2010年)

获取原文
获取原文并翻译 | 示例
           

摘要

HIV-1 subtype B is the most frequent strain in Peru. However, there is no available data about the genetic diversity of HIV-infected patients receiving highly active antiretroviral therapy (HAART) here. A group of 267 patients in the Peruvian National Treatment Program with virologic failure were tested for genotypic evidence of HIV drug resistance at the Instituto Nacional de Salud (INS) of Peru between March 2008 and December 2010. Viral RNA was extracted from plasma and the segments of the protease (PR) and reverse transcriptase (RT) genes were amplified by reverse transcriptase polymerase chain reaction (RT-PCR), purified, and fully sequenced. Consensus sequences were submitted to the HIVdb Genotypic Resistance Interpretation Algorithm Database from Stanford University, and then aligned using Clustal X v.2.0 to generate a phylogenetic tree using the maximum likelihood method. Intrasubtype and intersubtype recombination analyses were performed using the SCUEAL program (Subtype Classification by Evolutionary ALgo-rithms). A total of 245 samples (91%) were successfully genotyped. The analysis obtained from the HIVdb program showed 81.5% resistance cases (n=198). The phylogenetic analysis revealed that subtype B was predominant in the population (98.8%), except for new cases of A, C, and H subtypes (n=4). Of these cases, only subtype C was imported. Likewise, recombination analysis revealed nine intersubtype and 20 intrasubtype recombinant cases. This is the first report of the presence of HIV-1 subtypes C and H in Peru. The introduction of new subtypes and circulating recombinants forms can make it difficult to distinguish resistance profiles in patients and consequently affect future treatment strategies against HIV in this country.
机译:HIV-1 B型亚型是秘鲁最常见的菌株。但是,这里没有有关接受高活性抗逆转录病毒疗法(HAART)的HIV感染患者遗传多样性的可用数据。在秘鲁国家治疗计划中,有267名病毒学衰竭的患者在2008年3月至2010年12月间在秘鲁国立萨拉德医院(INS)进行了HIV耐药性的基因型证据测试。从血浆和片段中提取病毒RNA通过逆转录酶聚合酶链反应(RT-PCR)扩增蛋白酶(PR)和逆转录酶(RT)基因的一部分,纯化,并进行完全测序。共识序列已提交至斯坦福大学的HIVdb基因型抗性解释算法数据库,然后使用Clustal X v.2.0进行比对,以使用最大似然法生成系统树。使用SCUEAL程序(进化算法的亚型分类)进行亚型间和亚型间重组分析。共有245个样本(91%)成功进行了基因分型。从HIVdb程序获得的分析结果显示有81.5%的耐药病例(n = 198)。系统发育分析表明,除了新的A,C和H亚型(n = 4)外,B亚型在人群中占主导地位(98.8%)。在这些情况下,仅导入了C型。同样,重组分析显示有9个亚型和20个亚型重组病例。这是秘鲁首次出现HIV-1 C和H亚型的报告。引入新的亚型和循环的重组形式可能难以区分患者的抗药性,因此影响该国未来针对艾滋病毒的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号